Cancer Oesophagus Gefitinib
Retrospective study backs Iressa use in oesophageal cancer
November 5, 2014Research and Development, Sales and Marketing AstraZeneca, Cancer, Cancer Oesophagus Gefitinib, Iressa, gefitinib, oncology
A group of oesophageal cancer patients can increase their survival by six months or more if treated with AstraZeneca’s Iressa, …
Latest content
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
EnteroBiotix appoints former GSK Chief Medical Officer to board
November 3, 2026
